原发性硬化性胆管炎药物治疗进展OA北大核心CSTPCD
Advances in drug therapy for primary sclerosing cholangitis
原发性硬化性胆管炎(PSC)是一种以慢性进行性胆管炎症为特征的胆汁淤积性疾病,在我国发病率低,预后差,尚无药物治疗能改变PSC的进程,肝移植是唯一有效治疗手段,移植后5年生存率可达85%.基于PSC现状,药物治疗面临巨大挑战.目前治疗PSC的药物尚处于临床试验阶段,初步显示出应用前景,其中熊去氧胆酸是研究最广泛、最常用的药物.除此之外,还有很多新兴药物正在研究中.本文将围绕PSC最新药物治疗进展进行概述.
Primary sclerosing cholangitis(PSC)is a cholestatic disease characterized by chronic progressive bile duct inflammation and has a low incidence rate and poor prognosis in China.There is still no drug therapy that can change the course of PSC,and liver transplantation is the only effective treatment for PSC,with a 5-year survival rate of 85%after transplantation.Drug therapy for PSC is facing great challenges based on the current status of PSC.At present,drugs for the treatment of PSC are in the stage of clinical trials and have shown certain application prospect,among which ursodeoxycholic acid is the most widely studied and commonly used drug.In addition,there are many emerging drugs in the pipeline.This article summarizes the latest advances in drug therapy for PSC.
盛夏;纪庆明;李昕宇;王丽宏;牛俊奇
吉林大学第一医院 干部病房,长春 130021吉林大学第一医院 重症医学科,长春 130021哈尔滨医科大学附属第二医院内分泌与代谢病科,哈尔滨 150000吉林大学第一医院 感染病中心肝病科,长春 130021
胆管炎,硬化性熊去氧胆酸奥贝胆酸药物疗法
Cholangitis,SclerosingUrsodeoxycholic AcidObecholic AcidDrug Therapy
《临床肝胆病杂志》 2024 (005)
1032-1038 / 7
国家自然科学基金(82200666) National Natural Science Foundation of China(82200666)
评论